Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives

Varun Pathak*, Nupur Madhur Pathak, Christina L. O’Neill, Jasenka Guduric-Fuchs, Reinhold J. Medina

*Corresponding author for this work

Research output: Contribution to journalReview article

2 Citations (Scopus)
76 Downloads (Pure)

Abstract

Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells located in the endocrine pancreas in areas known as islets of Langerhans. The current standard-of-care for T1D is exogenous insulin replacement therapy. Recent developments in this field include the hybrid closed-loop system for regulated insulin delivery and long-acting insulins. Clinical studies on prediction and prevention of diabetes-associated complications have demonstrated the importance of early treatment and glucose control for reducing the risk of developing diabetic complications. Transplantation of primary islets offers an effective approach for treating patients with T1D. However, this strategy is hampered by challenges such as the limited availability of islets, extensive death of islet cells, and poor vascular engraftment of islets post-transplantation. Accordingly, there are considerable efforts currently underway for enhancing islet transplantation efficiency by harnessing the beneficial actions of stem cells. This review will provide an overview of currently available therapeutic options for T1D, and discuss the growing evidence that supports the use of stem cell approaches to enhance therapeutic outcomes.

Original languageEnglish
Number of pages13
JournalClinical Medicine Insights: Endocrinology and Diabetes
Volume12
DOIs
Publication statusPublished - 03 May 2019

    Fingerprint

Keywords

  • endothelial colony forming cells
  • immune therapies
  • induced pluripotent stem cells
  • insulin therapy
  • islet transplant
  • mesenchymal stem cells
  • Type 1 diabetes

Cite this